Effects Of Chinese Reimbursement Policy On Molecular Diagnosis And Therapy Of Nsclc From The Northern Part Of Henan Province

Gefitinib (Irisa) have significantly prolonged the overall survival of advanced non-small cell lung cancer (NSCLC) patients with the EGFR sensitivity mutations positive (EGFR+). Our hospital, the first affiliated hospital of Xinxiang Medical University, is the largest provincial Grade 3A hospital in northern part of Henan Province, most of the patients come from rural areas, and the incomes of the patients and their family members are too low to afford the expensive antitumor costs. Therefore, the expensive costs prevent the timely and sufficient treatment with gefitinib in patients with positive EGFR+ in our hospital.